Standard Life Aberdeen plc bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,802 shares of the biotechnology company’s stock, valued at approximately $923,000.

Several other hedge funds have also recently made changes to their positions in BMRN. Nissay Asset Management Corp Japan ADV boosted its stake in BioMarin Pharmaceutical by 4.8% during the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 12,078 shares of the biotechnology company’s stock valued at $1,138,000 after acquiring an additional 556 shares during the last quarter. Scout Investments Inc. boosted its stake in BioMarin Pharmaceutical by 125.6% during the 2nd quarter. Scout Investments Inc. now owns 214,099 shares of the biotechnology company’s stock valued at $20,168,000 after acquiring an additional 119,185 shares during the last quarter. Bellevue Group AG boosted its stake in BioMarin Pharmaceutical by 11.7% during the 2nd quarter. Bellevue Group AG now owns 49,519 shares of the biotechnology company’s stock valued at $4,665,000 after acquiring an additional 5,169 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in BioMarin Pharmaceutical by 68.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 427,999 shares of the biotechnology company’s stock valued at $40,318,000 after acquiring an additional 173,850 shares during the last quarter. Finally, Gideon Capital Advisors Inc. bought a new position in BioMarin Pharmaceutical during the 2nd quarter valued at $411,000.

BioMarin Pharmaceutical stock opened at $98.04 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.24 and a current ratio of 2.83. BioMarin Pharmaceutical Inc. has a 1 year low of $75.81 and a 1 year high of $106.20. The stock has a market capitalization of $17.41 billion, a PE ratio of -146.33 and a beta of 1.64.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.03). BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The business had revenue of $372.80 million during the quarter, compared to the consensus estimate of $359.25 million. During the same quarter in the previous year, the business posted ($0.21) earnings per share. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. research analysts expect that BioMarin Pharmaceutical Inc. will post -0.24 earnings per share for the current year.

In related news, insider Henry J. Fuchs sold 25,000 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $99.50, for a total value of $2,487,500.00. Following the sale, the insider now owns 142,667 shares of the company’s stock, valued at approximately $14,195,366.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Henry J. Fuchs sold 31,000 shares of the stock in a transaction dated Thursday, June 14th. The stock was sold at an average price of $90.00, for a total transaction of $2,790,000.00. Following the completion of the sale, the insider now directly owns 157,167 shares in the company, valued at approximately $14,145,030. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,638 shares of company stock worth $10,719,679. Corporate insiders own 1.90% of the company’s stock.

BMRN has been the topic of a number of research analyst reports. Canaccord Genuity increased their price objective on shares of BioMarin Pharmaceutical from $101.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Citigroup increased their price objective on shares of BioMarin Pharmaceutical to $108.00 and gave the company a “buy” rating in a research note on Tuesday, May 29th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, June 20th. ValuEngine upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Thursday, July 12th. Finally, Stifel Nicolaus raised their price target on shares of BioMarin Pharmaceutical from $102.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. BioMarin Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $116.28.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Featured Story: Google Finance Portfolio Tips and Tricks

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.